Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

REMIMAZOLAM vs REPOTRECTINIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

REMIMAZOLAM vs REPOTRECTINIB: Safety Overview

Metric REMIMAZOLAM REPOTRECTINIB
Total FAERS Reports 137 187
Deaths Reported 3 27
Death Rate 2.2% 14.4%
Hospitalizations 24 48
Average Patient Age 60.4 yrs 60.8 yrs
% Female Patients 41.5% 61.1%
FDA Approval Date Oct 6, 2020 Jun 11, 2024
Manufacturer Acacia Pharma, Ltd. E.R. Squibb & Sons, L.L.C.
Route INTRAVENOUS ORAL
Marketing Status Prescription Prescription